|Bid||0.00 x 0|
|Ask||383.00 x 0|
|Day's range||380.70 - 383.85|
|52-week range||291.80 - 393.70|
|Beta (5Y Monthly)||0.59|
|PE ratio (TTM)||23.64|
|Forward dividend & yield||8.15 (2.14%)|
|1y target est||326.96|
European shares clocked their best day in over a week on Friday, as upbeat jobs data from the United States and a surprise bounce in Chinese manufacturing tempered nerves around slowing global growth. U.S. job growth slowed less than expected in October, while a private business survey indicated that China's factory activity unexpectedly expanded at the fastest pace in more than two years last month. The latest data out of China is in contrast to an official survey published on Thursday, which had factory activity shrinking for the sixth straight month in October.
Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs. Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. The world's largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Does the October share price for Novo Nordisk A/S (CPH:NOVO B) reflect what it's really worth? Today, we will estimate...
Novo Nordisk A/S – Share repurchase programmeBagsværd, Denmark, 30 September 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.Under the programme initiated 9 August 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.6 billion in the period from 9 August 2019 to 30 October 2019.Since the announcement as of 23 September 2019, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKK Accumulated, last announcement3,951,950 1,372,668,150 23 September 2019130,000362.6247,141,236 24 September 2019130,000360.9246,919,325 25 September 2019125,000358.5444,817,391 26 September 2019125,000358.8044,849,806 27 September 2019125,000354.6044,324,908 Accumulated under the programme4,586,950 1,600,720,816 The details for each transaction made under the share repurchase programme are published on novonordisk.com.With the transactions stated above, Novo Nordisk owns a total of 35,146,994 B shares of DKK 0.20, corresponding to 1.5% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares. Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 27 September 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 27,987,962 B shares at an average share price of DKK 329.99 per B share equal to a transaction value of DKK 9,235,674,270.Further informationMedia: Anne Margrethe Hauge+45 4442 email@example.com Ken Inchausti (US)+1 609 240 firstname.lastname@example.org Investors: Peter Hugreffe Ankersen+45 3075 email@example.com Valdemar Borum Svarrer+45 3079 firstname.lastname@example.org Ann Søndermølle Rendbæk+45 3075 email@example.com Kristoffer Due Berg (US)+1 609 235 firstname.lastname@example.org Company announcement no. 56 / 2019Attachment * CA190930_Safe_Harbour
Bagsvaerd, Denmark, 20 September 2019 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide tablets), as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.Rybelsus®, the brand name for oral semaglutide in the US, is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet. The approval of Rybelsus® is based on the results from 10 PIONEER clinical trials which included 9,543 adults with type 2 diabetes. Rybelsus® more effectively lowered blood sugar than sitagliptin and empagliflozin. Furthermore, treatment with Rybelsus® resulted in up to 4.4 kg reduction in body weight. Rybelsus® demonstrated a safe and well-tolerated profile across the PIONEER programme, with the most common adverse event being mild to moderate nausea which diminished over time."We are very excited that we can make the first oral GLP-1 available in the US and thereby expand the treatment options for adults living with type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "Novo Nordisk has a very long legacy of developing innovative injectable medicines for people living with diabetes and, with the approval of Rybelsus®, we are now able to bring our innovation into the market for oral antidiabetics."Novo Nordisk plans to make Rybelsus® available to adults with type 2 diabetes in the US in the fourth quarter of 2019.Conference callOn 23 September at 8 am CEST, corresponding to 2 am EDT, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com.About Rybelsus®Rybelsus® (oral semaglutide) is an analogue of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). Rybelsus® is the first and only GLP-1 receptor agonist (RA) in a tablet. It is administered once daily and is approved for use in two therapeutic dosages, 7 mg and 14 mg.Rybelsus® is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency. Furthermore, Rybelsus® has been applied for a separate indication with the FDA for the reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, with expected review completion by Q1 2020.Further informationMedia: Mette Kruse Danielsen +45 4442 3883 email@example.com Ken Inchausti (US) +1 609 240 9429 firstname.lastname@example.org Investors: Peter Hugreffe Ankersen +45 3075 9085 email@example.com Valdemar Borum Svarrer +45 3079 0301 firstname.lastname@example.org Ann Søndermølle Rendbaek +45 3075 2253 email@example.com Kristoffer Due Berg (US) +1 609 235 2989 firstname.lastname@example.org Company announcement No 54 / 2019 Attachment * PR190920_oral_semaglutide_US_approval
European stocks clocked their fifth straight week of gains on Friday with investors buying into the oil and gas and banking sectors, and Novo Nordisk rising after U.S. approval of its oral diabetes drug. Investors also sought refuge in the so-called defensive sectors such as utilities, real-estate and food and beverages ahead of a week packed with economic data. The United Nations (UN) general assembly will also provide clues on the fallout from attacks on Saudi oil facilities last weekend and indications of a potential meeting between the presidents of Iran and the United States.
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
For two men trained as scientists, the bosses of Britain's major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit. With Britain set to leave the European Union within weeks, Pinder Sahota at the world's biggest insulin maker Novo Nordisk, and Sanofi's Hugo Fry have rebuilt operations to withstand the most turbulent of events.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
AstraZeneca made strides on Tuesday towards its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly. The British drugmaker said Farxiga was successful in reducing the risk of deadly heart attacks or disease progression in patients with a common form of heart failure in a clinical trial that could help win regulatory approval for its wider use.
Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement. "Novo Nordisk disagrees with the allegations and is prepared to defend the company in this matter," the company said. The securities lawsuit was filed by a number of shareholders who claims compensation worth a total of 11.785 billion Danish crowns (1.4 billion pounds) based on trading of Novo shares for two years from February 2015.
Novo Nordisk raised its sales forecast for this year thanks to growing demand for obesity drugs and a new injectable treatment for diabetes, now its growth engine as insulin sales decline. The Danish company is pinning its hopes on a relatively new treatment for type 2 diabetes as its older insulin drugs face political pressure over the soaring cost of the life-sustaining medicine in the United States. Sales of its new once-weekly injectable treatment, branded Ozempic, rose to 2.3 billion Danish crowns ($345 million) in the second quarter, which was higher than expected by analysts, sending shares in the world's top diabetes drugmaker 1.4% higher in early trading on Friday.
European shares slid on Friday with Italian stocks 2.5% lower on political uncertainty, while comments by U.S. President Donald Trump that he was not going to make a trade deal with China also weighed on sentiment. Italy's main index touched a two month low with its bank index tumbling 4.5% after the leader of the ruling League party, Matteo Salvini, pulled his support for the country's governing coalition on Thursday and called for fresh elections.
European shares fell on Friday, leading them to post a second straight week of losses, as worries about the stability of Italy's government rattled investors and concerns about Sino-U.S. trade tensions lingered. Milan's FTMIB index tumbled 1.6% with Italian banks hardest hit after the leader of the ruling League party, Matteo Salvini, pulled his support for the country's governing coalition on Thursday. Markets have recently been sensitive to political developments in Rome with Italian bond yields jumping each time there were doubts about the soundness of the government.